» Articles » PMID: 38169941

Rare Diseases: Still on the Fringes of Universal Health Coverage in Europe

Overview
Specialty Health Services
Date 2024 Jan 3
PMID 38169941
Authors
Affiliations
Soon will be listed here.
Abstract

Despite general advancements in population health indicators and universal health coverage, people living with rare diseases and their families still experience considerable unmet needs, including prolonged diagnostic journeys, limited treatment options, and a huge psychosocial burden due to the lack of coordinated, integrated care. Attainment of universal health coverage for rare diseases is dependent on fundamentally different health determinants and demands for different solutions. This involves consolidating expertise through Centers of Excellence, establishing efficient care pathways, fostering extensive collaboration at European and global levels in research and healthcare, and putting patients at the center of care. Furthermore, development of specific indicators and coding systems is crucial for monitoring progress. Only in this way Europe can strive towards a future where people living with rare diseases receive the same level of equitable, safe, high-quality healthcare as other members of the society, in alignment with the overarching goal of leaving no one behind.

Citing Articles

Impact of mental health in persons living with rare disease: Findings from the AMCP Market Insights Program.

Richardson T, Rice M, Lyon M, Kobernick M, Brackbill L J Manag Care Spec Pharm. 2024; 30(7-b Suppl):S1-S11.

PMID: 38953469 PMC: 11318483. DOI: 10.18553/jmcp.2024.30.7-b.s1.


Time to diagnosis and determinants of diagnostic delays of people living with a rare disease: results of a Rare Barometer retrospective patient survey.

Faye F, Crocione C, Anido de Pena R, Bellagambi S, Escati Penaloza L, Hunter A Eur J Hum Genet. 2024; 32(9):1116-1126.

PMID: 38755315 PMC: 11369105. DOI: 10.1038/s41431-024-01604-z.

References
1.
Stordeur S, Vrijens F, Leroy R . Reference centres for adults with rare and complex cancers - Policy recommendations to improve the organisation of care in Belgium. Rev Epidemiol Sante Publique. 2016; 64(1):1-6. DOI: 10.1016/j.respe.2015.11.006. View

2.
Rosenberg N, Stolwijk N, van den Berg S, Heus J, van der Wel V, van Gelder T . Development of medicines for rare diseases and inborn errors of metabolism: Toward novel public-private partnerships. J Inherit Metab Dis. 2023; 46(5):806-816. DOI: 10.1002/jimd.12605. View

3.
Derbel O, Heudel P, Cropet C, Meeus P, Vaz G, Biron P . Survival impact of centralization and clinical guidelines for soft tissue sarcoma (A prospective and exhaustive population-based cohort). PLoS One. 2017; 12(2):e0158406. PMC: 5291382. DOI: 10.1371/journal.pone.0158406. View

4.
Currie G, Szabo J . "It is like a jungle gym, and everything is under construction": The parent's perspective of caring for a child with a rare disease. Child Care Health Dev. 2018; 45(1):96-103. DOI: 10.1111/cch.12628. View

5.
Heon-Klin V . European Reference networks for rare diseases: what is the conceptual framework?. Orphanet J Rare Dis. 2017; 12(1):137. PMC: 5547471. DOI: 10.1186/s13023-017-0676-3. View